Literature DB >> 23599918

The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer.

Peter Doshi, Tom Jefferson.   

Abstract

Mesh:

Year:  2013        PMID: 23599918     DOI: 10.1001/jamainternmed.2013.3838

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  11 in total

1.  Court injunction threatens clinical data transparency push.

Authors:  Nuala Moran
Journal:  Nat Biotechnol       Date:  2013-07       Impact factor: 54.908

Review 2.  Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales.

Authors:  John P A Ioannidis; Fotini B Karassa; Eric Druyts; Kristian Thorlund; Edward J Mills
Journal:  Nat Rev Rheumatol       Date:  2013-09-03       Impact factor: 20.543

3.  Secrecy or transparency? The future of regulatory trial data.

Authors:  Beate Wieseler; Natalie McGauran
Journal:  CMAJ       Date:  2016-11-14       Impact factor: 8.262

4.  Time to ensure that clinical trial appropriate results are actually published.

Authors:  Rafael Dal-Ré; Arthur L Caplan
Journal:  Eur J Clin Pharmacol       Date:  2014-01-11       Impact factor: 2.953

Review 5.  Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.

Authors:  Dominic Way; Hortense Blazsin; Ragnar Löfstedt; Frederic Bouder
Journal:  Drug Saf       Date:  2017-01       Impact factor: 5.606

6.  Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency.

Authors:  Peter Doshi; Tom Jefferson
Journal:  Trials       Date:  2016-02-11       Impact factor: 2.279

Review 7.  IMPACT Observatory: tracking the evolution of clinical trial data sharing and research integrity.

Authors:  Karmela Krleža-Jerić; Mirko Gabelica; Rita Banzi; Marina Krnić Martinić; Bibiana Pulido; Mersiha Mahmić-Kaknjo; Ludovic Reveiz; Josip Šimić; Ana Utrobičić; Irena Hrgović
Journal:  Biochem Med (Zagreb)       Date:  2016-10-15       Impact factor: 2.313

8.  Restoring invisible and abandoned trials of gabapentin for neuropathic pain: a clinical and methodological investigation.

Authors:  Evan Mayo-Wilson; Xiwei Chen; Riaz Qureshi; Stephanie Dickinson; Lilian Golzarri-Arroyo; Hwanhee Hong; Carsten Görg; Tianjing Li
Journal:  BMJ Open       Date:  2021-06-30       Impact factor: 2.692

9.  Restoring invisible and abandoned trials: a call for people to publish the findings.

Authors:  Peter Doshi; Kay Dickersin; David Healy; S Swaroop Vedula; Tom Jefferson
Journal:  BMJ       Date:  2013-06-13

10.  Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports.

Authors:  Peter Doshi; Tom Jefferson
Journal:  BMJ Open       Date:  2013-02-26       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.